Modified mixed nanomicelles with collagen peptides enhanced oral absorption of Cucurbitacin B: preparation and evaluation

Polymer nanoparticles modified with collagen peptides (CPs) are an attractive strategy for the oral delivery of active ingredients from Chinese medicine. Thus, in the present study, collagen cationic CPs were simply separated using ion-exchange resin from bovine CPs, to modify mixed nanomicelles (MMs) on the surface to improve the oral bioavailability of Cucurbitacin B (CuB). The physicochemical property of micelles was characterized, which confirmed the successful modification of the nanomicelles. CPs-modified nanomicelles in vitro were found to significantly increase cellular uptake and transportation. Compared to unmodified micelles, the quantity of CPs-modified micelles internalized by Caco-2 cells were 3.74 times greater and the cumulative transportation flux (AP-BL) was 2.81 times greater. The membrane transportation process of CuB-MMs-CPs was found to be associated with energy consumption and clathrin- and caveolin-mediated endocytosis. In vivo studies performed on rats indicated that in comparison to CuB and CuB-MMs, the relative bioavailability of CuB-MMs-CPs increased by 3.43 times and 2.14 times, respectively. In addition, the tumor inhibition caused by CuB-MMs-CPs was increased significantly. Therefore, the nanomicelles co-modified with isolated CPs could act as attractive carriers for oral delivery of CuB.     

A self-assembly nanodrug delivery system based on amphiphilic low generations of PAMAM dendrimers-ursolic acid conjugate modified by lactobionic acid for HCC targeting therapy

Ursolic acid (UA), a natural triterpene acid, is a promising anti-cancer drug due to its inhibitory effect on tumor growth and metastasis. However, clinical translation of UA is limited by its poor water solubility and low bioavailability. To overcome these problems, herein an amphiphilic self-assembly nanodrug composed of UA, lactobionic acid (LA) and low-polyamidoamine (low-PAMAM) dendrimers is developed. This near-spherical nanodrug with a uniform size (~180 nm) demonstrated to have an enhanced cytotoxicity against liver cancer SMMC7721 cells, and could attenuate the migration and adhesion of SMMC7721 cells at non-toxic concentrations by suppressing metastasis-related protein MMP-9 expression. Furthermore, in vivo study indicates that the nanodrug exhibited prolonged circulation time in blood as well as increased AUC, MRT and C_max, and could effectively inhibit the tumor growth in H22 mice model. Overall, the UA-based nanodrug delivery system reported in the present work represents a novel strategy for targeted tumor therapy.     

2型糖尿病患者自我管理效果的研究进展

糖尿病患者的自我管理是在慢性病管理的基础上发展而来,在糖尿病健康管理中担当着重要的角色。本文从自我管理的概念内容、糖尿病患者自我管理的现状及影响因素、提高糖尿病患者自我管理措施等方面进行综述,为进一步改善2型糖尿病患者自我管理能力提供参考依据。     

Development and validation of an algorithm to identify drug-induced anaphylaxis in the Beijing Pharmacovigilance Database

International Journal of Clinical Pharmacy - Background Pharmacovigilance databases are utilized to identify serious adverse drug events (ADEs). In China, very few studies have evaluated the...     

术后化疗期乳腺癌患者心理痛苦及其心理僵化相关影响因素研究

目的明确术后化疗期乳腺癌患者心理痛苦现状及其心理僵化相关影响因素。方法采用心理痛苦温度计、认知融合问卷、接纳与行动问卷、正念注意觉知量表对204例术后化疗期乳腺癌患者进行调查。结果患者心理痛苦(4.80±1.04)分,阳性检出率97.1%。多元线性回归分析显示,经验性回避、认知融合、婚姻状况对患者的心理痛苦水平有影响(P0.05,P0.01)。结论术后化疗期的乳腺癌患者心理痛苦水平较高,经验性回避、认知融合、婚姻状况是术后化疗期乳腺癌患者心理痛苦的独立影响因素。帮助患者降低经验性回避和认知融合水平,有利于缓解其心理痛苦。     

肾上腺非霍奇金淋巴瘤的超声影像学表现

目的 探讨肾上腺非霍奇金淋巴瘤的声像图特征。方法 回顾性分析经穿刺活检或手术病理证实的13例肾上腺淋巴瘤的超声声像图特征。结果 13例肾上腺淋巴瘤患者累及双侧6例,单侧7例,共19个病灶,均为非霍奇金淋巴瘤弥漫大B细胞型。肿块大小3.0~14.0 cm,平均(7.99±3.08)cm。18个病灶为低回声,1个表现为杂乱回声。内部回声均匀者10个,不均匀者9个,其中内部可见条索状稍强回声者7个,伴小片状无回声区4个。彩色多普勒示68.42%(13/19)肿块内未见明显血流信号,仅31.58%(6/19)内探及点状血流信号。此外,3个较大病灶不同程度累及同侧肾脏及其周围组织,1个伴下腔静脉栓子形成。结论 肾上腺非霍奇金淋巴瘤超声声像图多表现为边界清楚的规则低回声团块,肿瘤内无明显或仅见少许点状血流信号,但对于内部回声不均匀伴有液化等征象的病灶,不能完全除外淋巴瘤的可能。     

Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay

Circulating tumor cells (CTCs) have been proposed to be an active source of metastasis or recurrence of hepatocellular carcinoma (HCC). The enumeration and characterization of CTCs has important clinical significance in recurrence prediction and treatment monitoring in HCC patients. We previously developed a unique method to separate HCC CTCs based on the interaction of the asialoglycoprotein receptor (ASGPR) expressed on their membranes with its ligand. The current study applied the ligand-receptor binding assay to a CTC-chip in a microfluidic device. Efficient capture of HCC CTCs originates from the small dimensions of microfluidic channels and enhanced local topographic interactions between the microfluidic channel and extracellular extensions. With the optimized conditions, a capture yield reached > 85% for artificial CTC blood samples. Clinical utility of the system was further validated. CTCs were detected in all the examined 36 patients with HCC, with an average of 14 ± 10/2 mL. On the contrary, no CTCs were detected in healthy, benign liver disease or non-HCC cancer subjects. The current study also successfully demonstrated that the captured CTCs on our CTC-chip were readily released with ethylene diamine tetraacetic acid (EDTA); released CTCs remained alive and could be expanded to form a spheroid-like structure in a 3-dimensional cell culture assay; furthermore, sensitivity of released CTCs to chemotherapeutic agents (sorafenib or oxaliplatin) could be effectively tested utilizing this culture assay. In conclusion, the methodologies presented here offer great promise for accurate enumeration and easy release of captured CTCs, and released CTCs could be cultured for further functional studies.